Esperion Therapeutics Inc (NASDAQ:ESPR) major shareholder Target N. V. Biotech purchased 50,000 shares of the stock in a transaction dated Thursday, March 14th. The stock was purchased at an average price of $49.89 per share, with a total value of $2,494,500.00. Following the completion of the acquisition, the insider now directly owns 3,522,964 shares in the company, valued at approximately $175,760,673.96. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Major shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.
NASDAQ:ESPR traded up $0.84 during midday trading on Friday, reaching $49.87. 891,799 shares of the company traded hands, compared to its average volume of 582,098. Esperion Therapeutics Inc has a twelve month low of $33.06 and a twelve month high of $79.30. The firm has a market capitalization of $1.32 billion, a P/E ratio of -6.61 and a beta of 2.17.
A number of hedge funds have recently made changes to their positions in the business. BB Biotech AG boosted its position in Esperion Therapeutics by 3.4% during the 4th quarter. BB Biotech AG now owns 3,392,964 shares of the biopharmaceutical company’s stock worth $156,076,000 after acquiring an additional 110,000 shares during the period. Meditor Group Ltd boosted its position in Esperion Therapeutics by 1.9% during the 4th quarter. Meditor Group Ltd now owns 2,679,835 shares of the biopharmaceutical company’s stock worth $123,272,000 after acquiring an additional 50,000 shares during the period. BlackRock Inc. boosted its position in Esperion Therapeutics by 4.1% during the 3rd quarter. BlackRock Inc. now owns 1,878,905 shares of the biopharmaceutical company’s stock worth $83,367,000 after acquiring an additional 73,673 shares during the period. Vanguard Group Inc boosted its position in Esperion Therapeutics by 6.5% during the 3rd quarter. Vanguard Group Inc now owns 1,649,168 shares of the biopharmaceutical company’s stock worth $73,173,000 after acquiring an additional 99,946 shares during the period. Finally, Vanguard Group Inc. boosted its position in Esperion Therapeutics by 6.5% during the 3rd quarter. Vanguard Group Inc. now owns 1,649,168 shares of the biopharmaceutical company’s stock worth $73,173,000 after acquiring an additional 99,946 shares during the period. Institutional investors own 99.43% of the company’s stock.
About Esperion Therapeutics
Esperion Therapeutics, Inc, a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its lead product candidate is bempedoic acid/ezetimibe combination pill, a non-statin, orally available, LDL-C lowering therapy for patients with hypercholesterolemia and with atherosclerotic cardiovascular disease, and/or heterozygous familial hypercholesterolemia that is in Phase III long-term safety and tolerability study.
Read More: Derivative
Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.